Effect of thalidomide on the efficacy of diffuse large B-cell lymphoma and the expressions of Th17 cells and related cytokines
10.3760/cma.j.issn.1009-9921.2018.05.002
- VernacularTitle: 沙利度胺对弥漫大B细胞淋巴瘤疗效及Th17细胞和相关细胞因子表达的影响
- Author:
Li LI
1
;
Yifei YANG
2
;
Junchao YANG
1
;
Liyun ZHOU
1
Author Information
1. Department of Hematology, Affiliated Hospital of Hebei University of Engineering, Handan 056002, China
2. Department of Discipline Construction and Graduate Education, Affiliated Hospital of Hebei University of Engineering, Handan 056002, China
- Publication Type:Journal Article
- Keywords:
Lymphoma, large B-cell, diffuse;
Drug therapy, combination;
Thalidomide;
Th17 cells;
Survival period
- From:
Journal of Leukemia & Lymphoma
2018;27(5):263-267
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of thalidomide on the expressions of Th17 cells, interleukin 17 (IL-17), macrophage inflammatory protein 3α (MIP3α) in peripheral blood of patients with diffuse large B-cell (DLBCL) and 3-year survival rate.
Methods:Sixty patients with DLBCL from January 2009 to January 2013 in the Affiliated Hospital of Hebei University of Engineering were enrolled. According to envelope method, the patients were randomly divided into the combined group (n = 30, thalidomide combined with CHOP regimen) and chemotherapy group (n = 30, CHOP regimen alone). Clinical adverse reactions, efficacy, the expressions of Th17 cells, IL-17, MIP3α in peripheral blood before and after treatment, and 3-year survival rate between two groups were compared.
Results:The total effective rate and 3-year survival rate were 73.3% (22/30) vs. 46.7% (14/30), 87.4% vs. 40.7% respectively in the combined group and the chemotherapy group (both P < 0.05). The levels of Th17 cells percentage and the expression level of IL-17 before and after treatment in combined group were (0.52±0.14)% vs. (1.61±0.53)%, (5.61±0.75) pg/ml vs. (8.87±1.84) pg/ml, and the difference was statistically significant (both P < 0.05). However, the expression levels of Th17 cells and IL-17 before and after treatment in the chemotherapy group were (0.75±0.05)% vs. (0.74±0.07)%, (5.69±0.29) pg/ml vs. (5.26±0.24) pg/ml, and there was no statistical difference (both P > 0.05). The levels of IL-17 and MIP3α mRNA in peripheral serum before and after treatment in the combined group were 8.51±0.23 vs.13.96±0.89, 27.4±1.5 vs. 83.0±8.5 (both P < 0.05). While in the treatment group before and after treatment the above mentioned were 8.85±0.32 vs. 9.45±0.55, 23.7±1.8 vs. 38.7±5.5, and the difference was no statistically significant (both P > 0.05). There was no statistical difference in the adverse reactions between the combined group and the chemotherapy group (P > 0.05).
Conclusion:Thalidomide may prolong survival time of DLBCL patients by intervening Th17 cells and associated cytokines.
